POST GRADUATE SCHOLAR THESIS LECTURE REVIEW OF 1. PHYSIOLOGY OF BLOOD PRESSURE 2. PATHOPHYSIOLOGY OF HYPERTENSION

Reading File

Finding Sources

Searching PubMed

"hypertension" AND "pathophysiology"

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Searching the Web

physiology blood pressure regulation cardiac output peripheral resistance baroreceptors 2024 2025

Loading Image

I now have all the material needed for a comprehensive postgraduate-level thesis lecture review. Here is the full document:

POST GRADUATE SCHOLAR THESIS LECTURE REVIEW

PHYSIOLOGY OF BLOOD PRESSURE AND PATHOPHYSIOLOGY OF HYPERTENSION

Source: Fuster and Hurst's The Heart, 15th Edition | Histology: A Text and Atlas with Correlated Cell and Molecular Biology | Comprehensive Clinical Nephrology, 7th Edition

PART I: PHYSIOLOGY OF BLOOD PRESSURE

1.1 The Fundamental Equation of Blood Pressure

Blood pressure (BP) regulation is understood through the following governing relationship:

BP = Cardiac Output (CO) × Total Peripheral Resistance (TPR)

This equation frames the two major determinants of arterial pressure - the pump (heart) and the resistance (vasculature). However, long-term BP control and the pathogenesis of hypertension require a third dimension: renal regulation of body fluid volume and time-dependent interactions among multiple control systems.

1.2 Cardiac Output and Its Determinants

Cardiac output is the sum of blood flows to all tissues and organs in the body. Normal distribution of CO at rest:

Figure 1. Relationship between cardiac output, peripheral blood flow, and venous return. CO is distributed as: Brain 20%, Kidneys 20%, Muscle 20%, GI tract 25%, Heart 5%, Skin/other 10%.

Key physiological points:

CO is determined not only by cardiac pumping ability, but critically by the peripheral circulation and tissue metabolic demands
Amputation of a limb reduces venous return and CO without significantly altering BP - demonstrating that CO adapts to peripheral needs
During exercise, pregnancy, or growth, increased CO may occur without BP change, because TPR falls proportionally
In severe heart failure, cardiac pumping becomes limiting, but under normal conditions CO is governed by metabolic demands of tissues

Determinants of CO:

Stroke Volume (SV) = preload (ventricular filling), afterload (wall stress during ejection), contractility (inotropy)
Heart Rate (HR) - regulated by the sinoatrial node under autonomic and humoral control
CO = SV × HR (normal resting value: ~5 L/min)

1.3 Total Peripheral Resistance

TPR is the aggregate resistance offered by the entire systemic vasculature. From Poiseuille's law:

Resistance = (8 × viscosity × length) / (π × radius⁴)

The radius (r) dominates because resistance varies with r⁴. Therefore, even small changes in arteriolar caliber have enormous effects on resistance and perfusion pressure.

Arterioles are the principal site of TPR regulation - they are the "resistance vessels" whose tone is modulated by:

Neurogenic factors (sympathetic vasoconstrictor tone)
Hormonal factors (angiotensin II, endothelin, vasopressin)
Metabolic autacoids (adenosine, CO₂, H⁺, lactate)
Endothelium-derived signals (nitric oxide, prostacyclin, endothelin-1)

1.4 Short-Term Blood Pressure Regulation

1.4.1 The Baroreflex (Baroreceptor Reflex)

The arterial baroreceptors - high-pressure mechanoreceptors located in the carotid sinus and aortic arch - respond to vessel wall stretch caused by elevated arterial pressure:

Increased BP → increased wall stretch → increased baroreceptor firing frequency
Afferent signals travel via CN IX (carotid sinus nerve/Hering's nerve) and CN X (aortic depressor nerve) to the Nucleus Tractus Solitarius (NTS) in the medulla oblongata
NTS modulates activity of sympathetic and parasympathetic (vagal) neurons in the cardiovascular center
Net result: decreased sympathetic output + increased vagal tone → decreased HR, decreased contractility, vasodilation → BP falls back toward normal

This reflex provides rapid, beat-to-beat BP stabilization and can alter BP within seconds.

Maximum carotid sinus sensitivity occurs near normal mean arterial pressure (MAP), so tiny deviations from the "set point" trigger powerful corrective responses
The baroreflex is reset upward in chronic hypertension (see Part II)

1.4.2 Chemoreceptor Reflexes

Peripheral chemoreceptors (carotid and aortic bodies) respond to hypoxia, hypercapnia, and acidosis - stimulating the vasomotor center to increase sympathetic tone
Central chemoreceptors in the medulla respond primarily to CO₂/pH changes in cerebrospinal fluid

1.4.3 CNS Ischemic Response

When cerebral perfusion pressure falls critically (MAP < 50 mmHg), the vasomotor center itself becomes ischemic and fires maximally, producing the Cushing reflex - a massive surge in sympathetic output raising BP as an emergency response.

1.5 Long-Term Blood Pressure Regulation: Tissue Blood Flow Autoregulation

Autoregulation is the intrinsic ability of each tissue to maintain constant blood flow over a wide range of perfusion pressures (approximately 75-150 mmHg MAP).

Figure 2. Autoregulation curves: In normal individuals (blue), cerebral blood flow remains constant across a wide MAP range. In chronic hypertension (red), the autoregulatory curve shifts rightward - patients are protected from high pressures but vulnerable to hypoperfusion at "normal" MAPs. In impaired autoregulation (green), flow is pressure-dependent.

Mechanisms:

Acute (seconds to minutes): Myogenic response (Bayliss effect) - vessel wall contracts in response to stretch. Metabolic vasodilation (local O₂ depletion, CO₂/H⁺ accumulation) restores flow after vasoconstriction
Chronic (days to weeks): Structural vascular remodeling - wall thickening, capillary rarefaction (reduced capillary density), angiogenesis with tissue growth

Clinical implication for hypertension: Elevated TPR in chronic hypertension is often a consequence (autoregulatory response) rather than a primary cause, as vessels constrict to protect tissues from chronically elevated perfusion pressure.

1.6 The Renal-Body Fluid System: The Ultimate Long-Term BP Controller

The kidneys exert the dominant influence on long-term BP through pressure natriuresis - the relationship between arterial pressure and urinary sodium excretion:

As BP rises → kidneys excrete more sodium and water (natriuresis and diuresis)
This reduces blood volume → reduces venous return → reduces CO → BP falls toward normal
Conversely, a fall in BP → sodium and water retention → volume expansion → restored BP

This system is the only one capable of indefinitely maintaining sodium balance at a precise blood pressure level. Any sustained alteration in BP is therefore a reflection of a reset or impaired pressure-natriuresis relationship.

1.7 The Renin-Angiotensin-Aldosterone System (RAAS)

The RAAS is the central hormonal axis integrating renal, cardiovascular, and adrenal function in BP regulation:

RAAS cascade and pharmacological sites of intervention

Figure 3. The RAAS cascade: Liver produces angiotensinogen → converted by renin (from juxtaglomerular cells) to Angiotensin I → converted by ACE in lung endothelium to Angiotensin II → acts on arterioles (vasoconstriction) and adrenal cortex (aldosterone release). Aldosterone acts on the collecting duct to reabsorb Na⁺, excrete K⁺, and retain water. Pharmacological targets are shown (ACE inhibitors, ARBs, renin inhibitors, mineralocorticoid receptor blockers).

Steps in RAAS activation:

Step	Site	Event
1	Liver	Synthesis of angiotensinogen (alpha-2 globulin)
2	JGA of kidney	Renin released in response to: ↓ renal perfusion pressure, ↓ Na⁺ delivery to macula densa, ↑ sympathetic (β₁) stimulation
3	Bloodstream	Renin cleaves angiotensinogen → Angiotensin I (decapeptide)
4	Pulmonary capillary endothelium	ACE cleaves 2 amino acids → Angiotensin II (octapeptide - most potent vasoconstrictor)
5	Systemic arterioles	Ang II → vasoconstriction (AT₁ receptors) → ↑ TPR
6	Adrenal zona glomerulosa	Ang II → aldosterone release → Na⁺/water retention → ↑ blood volume
7	Kidney	Ang II → direct tubular Na⁺ reabsorption, reset pressure-natriuresis curve upward

Additional Ang II effects:

Stimulates ADH (vasopressin) release from posterior pituitary
Stimulates thirst via hypothalamic centers
Stimulates sympathetic ganglia and adrenal medulla (positive feedback)
Promotes vascular smooth muscle hypertrophy (trophic/remodeling effect)

1.8 The Sympathetic Nervous System in BP Regulation

The sympathetic nervous system (SNS) can:

Raise BP within seconds by causing vasoconstriction, increased heart rate, and enhanced cardiac contractility
Sudden SNS inhibition can reduce BP to as low as half of normal within 1 minute

The SNS plays a major long-term role through renal sympathetic innervation - extensive fibers reach renal blood vessels, the juxtaglomerular apparatus, and renal tubules:

Stimulate renin secretion
Promote sodium reabsorption in proximal tubule, loop of Henle, and distal segments
Impair renal pressure-natriuresis (shift the curve upward)

1.9 Other Vasoactive Systems

System	BP Effect	Mechanism
Nitric Oxide (NO)	Vasodilatory	Endothelium-derived, activates guanylate cyclase in VSMCs → ↓ Ca²⁺ → relaxation
Endothelin-1 (ET-1)	Vasoconstrictive	Most potent endogenous vasoconstrictor; acts via ETA receptors
Atrial Natriuretic Peptide (ANP)	Vasodilatory/natriuretic	Released by atrial cardiomyocytes in response to stretch; increases GFR, inhibits tubular Na⁺ reabsorption, suppresses RAAS
Prostacyclin (PGI₂)	Vasodilatory	Endothelium-derived; opposes thromboxane A₂
Vasopressin (ADH)	Vasoconstrictive	V₁ receptors on vessels; also promotes water reabsorption via V₂ receptors
Bradykinin	Vasodilatory	Stimulates NO and PGI₂ release; degraded by ACE (hence ACE inhibitors also preserve bradykinin)

PART II: PATHOPHYSIOLOGY OF HYPERTENSION

2.1 Definition and Classification

Hypertension is defined as a sustained elevation in arterial blood pressure above accepted thresholds. Based on current JNC/ACC/AHA guidelines:

Category	Systolic (mmHg)	Diastolic (mmHg)
Normal	< 120	< 80
Elevated	120-129	< 80
Stage 1 HTN	130-139	80-89
Stage 2 HTN	≥ 140	≥ 90
Hypertensive crisis	> 180	> 120

Classification by cause:

Primary (Essential) Hypertension: >90% of all cases; no single identifiable cause
Secondary Hypertension: <10% of cases; identifiable underlying disorder

2.2 Blood Flow Regulation in Hypertension

One characteristic of most patients with chronic hypertension is elevated TPR. However, tissue blood flows remain approximately normal - indicating that increased resistance is an autoregulatory adaptation, not a primary cause:

The autoregulatory curve shifts rightward in chronic hypertension (Figure 2 above)
This protects tissues from overperfusion at high BP, but renders patients vulnerable to ischemia at "normal" MAPs (e.g., rapid antihypertensive treatment can precipitate cerebral ischemia)
Hemodynamic pattern in non-obese primary hypertension: normal CO, normal tissue blood flow, elevated TPR

2.3 The Central Role of the Kidneys: Pressure Natriuresis and Hypertension

The kidney is the final arbiter of long-term BP. For hypertension to be sustained, the pressure-natriuresis relationship must be impaired or reset. This can occur through:

Reduced nephron number (congenital or acquired) - decreased filtration surface means natriuresis requires higher BP; slope of pressure-natriuresis curve decreases (salt-sensitive pattern)
Decreased glomerular filtration coefficient (Kf) - similar effect; ↑ glomerular pressure, risk of glomerular injury
Increased tubular sodium reabsorption - e.g., excess aldosterone, increased sympathetic tone, primary ENaC activation (Liddle syndrome)
Increased preglomerular resistance - renal artery stenosis or aortic coarctation causes a "parallel shift" in the pressure-natriuresis curve (salt-insensitive pattern); renin and Ang II transiently elevated but normalize as a new equilibrium is established at a higher BP

Salt-Sensitive vs. Salt-Insensitive Hypertension:

Feature	Salt-Sensitive	Salt-Insensitive
Cause	↓ nephron mass, ↓ Kf, ↑ tubular reabsorption	↑ preglomerular resistance
Pressure-natriuresis curve	Decreased slope	Parallel rightward shift
Glomerular injury	Yes (↑ glomerular pressure)	No (glomeruli protected by upstream resistance)
Plasma renin activity	Low-normal	Elevated initially, then normal

(Source: Fuster and Hurst's The Heart, 15th Edition, Table MLE5-3)

2.4 The Sympathetic Nervous System in Hypertension

Excessive SNS activation is a major contributor to hypertension through:

Renal nerve activation: Even mild increases in renal sympathetic activity stimulate renin secretion and Na⁺ reabsorption in the proximal tubule, loop of Henle, and distal segments - impairing pressure-natriuresis
Vascular effects: Sympathetic vasoconstriction increases TPR
Cardiac effects: Increased HR and contractility raise CO

Evidence from Renal Denervation (RDN):

RDN reduces BP in experimental hypertension models (spontaneously hypertensive rats)
Human trials (SYMPLICITY series): catheter-based radiofrequency RDN lowered office BP for up to 36 months in obese patients with resistant hypertension
Current limitation: catheter-based RDN achieves only <50% nerve ablation; branches of main renal artery are inaccessible; renal nerves may regrow

Mechanisms of SNS activation in primary hypertension:

Hypothalamic CRH: Obesity and stress chronically elevate corticotropin-releasing hormone, activating the hypothalamic-pituitary-adrenal axis and the SNS
Leptin: Adipose tissue-derived hormone; stimulates the SNS (hypothalamic pathways) - links obesity to hypertension
Melanocortin (MC4R) pathway: Leptin and central nervous system melanocortin receptor activation raise sympathetic outflow and BP

2.5 The RAAS in Hypertension

While 24-hour urine renin levels in essential hypertension are often "normal," this should be interpreted in context: any measurable renin activity in the setting of volume expansion is inappropriately elevated. The "lesion" in chronic essential hypertension is now believed to be excessive production of Angiotensin II, particularly in pulmonary endothelium.

Key pathological mechanisms:

Ang II impairs the pressure-natriuresis relationship - shifts it upward, requiring higher BP to achieve the same sodium excretion
Ang II promotes vascular hypertrophy and remodeling - structural narrowing of arterioles (functional narrowing → anatomical narrowing)
Ang II promotes oxidative stress via NADPH oxidase activation → superoxide generation → scavenges NO → endothelial dysfunction
Chronic Ang II excess promotes glomerulosclerosis and nephron loss - a vicious cycle maintaining hypertension

2.6 Nitric Oxide Deficiency and Endothelial Dysfunction

Reduced endothelial-derived nitric oxide (EDNO) synthesis is a key mechanism in hypertension:

Figure 4. Consequences of reduced renal endothelial NO synthesis: increased sensitivity to vasoconstrictors (Ang II, norepinephrine), increased basal renal vascular resistance, increased renal tubular Na⁺ transport, and increased renin release. All four mechanisms converge to reduce renal pressure natriuresis and ultimately produce hypertension.

Mechanisms of reduced NO in hypertension:

Oxidative stress: superoxide (O₂⁻) reacts with NO to form peroxynitrite (ONOO⁻), reducing NO bioavailability
eNOS uncoupling: insufficient tetrahydrobiopterin (BH4) as cofactor causes eNOS to produce superoxide instead of NO
Reduced L-arginine substrate availability
Hemodynamic shear stress reduction (physical inactivity)

2.7 Oxidative Stress in Hypertension

Considerable evidence supports a role for reactive oxygen species (ROS) in experimental hypertension:

Dahl Salt-sensitive (DS) rats: increased vascular and renal superoxide production, increased H₂O₂, decreased superoxide dismutase expression
Stroke-prone spontaneously hypertensive rats: elevated superoxide, decreased total antioxidant capacity
Chronic Tempol (SOD mimetic) administration significantly decreases BP and attenuates renal damage in animal models
Ang II hypertension is partly mediated by NADPH oxidase-derived superoxide (apocynin reduces BP)

However, clinical translation has been disappointing: Large-scale clinical trials of antioxidant therapy (Vitamins C and E) have failed to confirm BP-lowering effects in humans. Assessment of ROS in human tissues is technically challenging due to low levels and short half-lives.

2.8 Atrial Natriuretic Peptide (ANP): A Counterregulatory System

ANP is a 28-amino-acid peptide released from atrial cardiomyocytes in response to stretch/volume expansion:

Enhances GFR (but not prerequisite for natriuresis)
Directly inhibits renal tubular Na⁺ reabsorption
Alters medullary blood flow and peritubular capillary physical factors
Suppresses antinatriuretic hormones (Ang II, aldosterone)

In primary hypertension, plasma ANP is elevated in volume-expanded states. Exogenous ANP infusions at physiological concentrations can lower BP. Deficient ANP signaling - from reduced release or receptor downregulation - may contribute to impaired natriuresis in salt-sensitive hypertension.

2.9 Pathophysiology of Primary (Essential) Hypertension

Essential hypertension accounts for >90% of all cases and is multifactorial:

2.9.1 Known Contributing Causes

Overweight/Obesity - The Dominant Risk Factor (65-75% of risk for primary hypertension):

Obesity raises BP through multiple mechanisms:

Increased renal tubular sodium reabsorption - adipose tissue compresses the kidneys (renal adipose capsule), directly increasing sodium retention ("reno-pressor effect" of obesity)
SNS activation - leptin from adipose tissue activates hypothalamic SNS outflow
RAAS activation - adipose tissue locally produces angiotensinogen and angiotensin; insulin resistance raises Ang II levels
Insulin resistance and hyperinsulinemia - insulin directly stimulates renal sodium reabsorption and SNS activity
Inflammation - adipose tissue macrophages and cytokines (TNF-α, IL-6) impair NO bioavailability and promote vascular inflammation

Hemodynamic pattern in obesity-hypertension differs from non-obese hypertension:

Elevated CO (to meet metabolic demands of excess adipose tissue)
Relatively normal TPR initially (may rise later due to autoregulation)
Expanded blood volume

Other modifiable causes:

Excess dietary sodium chloride
Excess alcohol intake
Sedentary lifestyle
Low dietary potassium

2.9.2 Genetic Determinants

Although primary hypertension has no single gene mutation, BP has substantial heritability (~30-50%). Genome-wide association studies have identified >1000 genetic loci associated with BP. Monogenic forms (rare but mechanistically instructive):

Genetic Syndrome	Mechanism	Inheritance	Treatment
Liddle Syndrome	Gain-of-function ENaC mutation → ↑ Na⁺ reabsorption	AD	Amiloride, triamterene (not aldosterone antagonists)
FH-I / GRA	Chimeric gene → ACTH-driven aldosterone synthase	AD	Glucocorticoids (suppress ACTH)
FH-II	Aldosterone excess, normal ACTH	AD	Mineralocorticoid receptor antagonist
Gordon Syndrome (PHA Type II)	SPAK/WNK kinase gain → ↑ NCC activity	AD	Thiazide diuretics
AME (Apparent Mineralocorticoid Excess)	11β-HSD2 deficiency → cortisol activates MR	AR	Dexamethasone, MR antagonist, amiloride
Brachydactyly + Hypertension	Chromosome 12p11 vascular anomaly	AD	Milrinone

(Source: Fuster and Hurst's The Heart, Table 5-5)

2.10 Pathophysiology of Secondary Hypertension

2.10.1 Renovascular Hypertension (RAS / Goldblatt Hypertension)

Mechanism: Renal artery stenosis (atherosclerosis or fibromuscular dysplasia) → reduced renal perfusion pressure → JGA activation → ↑ renin → ↑ Ang II → ↑ aldosterone
In two-kidney one-clip (2K1C) model: the clipped kidney drives RAAS; contralateral kidney has natriuresis; renin-mediated, salt-insensitive hypertension
In one-kidney one-clip (1K1C) model: volume-dependent hypertension; renin normalizes once volume is expanded
Preglomerular resistance is protective for glomeruli in the stenosed kidney but the contralateral kidney faces elevated pressure → glomerular injury risk

2.10.2 Primary Hyperaldosteronism (Conn Syndrome)

Excessive aldosterone from adrenal adenoma or bilateral hyperplasia
Mechanism: continuous Na⁺ retention, K⁺ wasting, hypokalemia, suppressed renin
The aldosterone-to-renin ratio (ARR) > 30 with aldosterone > 15 ng/dL is diagnostic screening test
Most common surgically correctable form of hypertension

2.10.3 Pheochromocytoma

Rare (0.05% of hypertensive patients) but potentially fatal if unrecognized
Neuroectodermal chromaffin cell tumor; 85% adrenal medulla, 15-30% extraadrenal
Mechanism: excessive catecholamine (epinephrine/norepinephrine) release
Norepinephrine predominant: α-adrenergic vasoconstriction → sustained diastolic hypertension
Epinephrine predominant: β-adrenergic cardiac stimulation → mainly systolic hypertension with tachycardia, sweating, tremors, flushing; 5% remain normotensive
Hypertension may be sustained or paroxysmal depending on secretory pattern

2.10.4 Cushing Syndrome

Glucocorticoid excess (endogenous or exogenous): cortisol activates mineralocorticoid receptors (bypassing 11β-HSD2 saturation) → Na⁺ retention
Also increases angiotensinogen synthesis → ↑ RAAS
Clinical features: central obesity, striae, buffalo hump, moon face, hyperglycemia

2.10.5 Preeclampsia

New-onset hypertension (SBP ≥140 or DBP ≥90 mmHg) after 20 weeks of gestation, with proteinuria and multisystem involvement
Mechanism: abnormal cytotrophoblast invasion of spiral arterioles → placental ischemia → maternal vascular endothelial dysfunction → ↑ ET-1, thromboxane, superoxide, ↑ vascular sensitivity to Ang II, ↓ NO and prostacyclin
Key pathway: anti-angiogenic sFlt-1 (soluble VEGF receptor) is released by the ischemic placenta → scavenges VEGF and PlGF → endothelial injury → hypertension, proteinuria, multi-organ damage
Hypertension remits after delivery - placenta is the central driver

2.10.6 Coarctation of the Aorta

Structural narrowing, usually at the level of the ductus arteriosus
Mechanism: increased preglomerular resistance to kidneys (distal to coarctation) activates RAAS - salt-insensitive hypertension pattern
Upper extremity hypertension with lower extremity hypotension/absent pulses is the classic presentation

2.11 Target Organ Damage in Hypertension

Sustained hypertension injures multiple organs:

Organ	Pathological Change	Clinical Consequence
Heart	LV hypertrophy (concentric) → diastolic dysfunction → systolic failure; coronary artery disease	Heart failure, arrhythmias, sudden cardiac death
Brain	Lacunar infarcts (small vessel disease), hemorrhagic stroke, hypertensive encephalopathy	Stroke, vascular dementia, hypertensive emergency
Kidneys	Benign nephrosclerosis (hyalinosis of afferent arterioles, glomerulosclerosis) → nephron loss → CKD	Progressive CKD, ESRD - creates a vicious cycle
Retina	Arteriovenous nipping, copper/silver wiring (grade 1-2), cotton wool spots (grade 3), papilledema (grade 4)	Visual impairment, optic neuropathy
Large vessels	Accelerated atherosclerosis, aortic dissection, aneurysm formation	Aortic dissection, peripheral vascular disease

2.12 The Vicious Cycle of Hypertension and Renal Damage

A clinically critical concept:

Hypertension → Glomerular hypertension/hyperfiltration
             → Glomerular injury → Nephron loss
             → Reduced filtration surface
             → Impaired pressure-natriuresis
             → Further sodium retention
             → Worsening hypertension (self-perpetuating cycle)

This is why effective antihypertensive therapy (especially RAAS blockade) is nephroprotective beyond BP reduction alone - by reducing glomerular hypertension directly.

2.13 Summary: Integrated Model of Hypertension Pathophysiology

The following unified model integrates all mechanisms:

PRIMARY DRIVER(S)
      ↓
[Renal impairment of pressure-natriuresis] ← Central axis
      ↑                    ↑                    ↑
SNS excess          RAAS activation       ↓ NO / oxidative stress
(obesity, CNS)    (RAS, Conn, Ang II)    (endothelial dysfunction)
      ↑                    ↑
Genetic factors     Environmental factors
(monogenic or       (obesity, Na⁺ excess,
 polygenic)          sedentary, alcohol)
      ↓
Sustained ↑ BP → Target organ damage

The kidneys must be impaired (structurally or functionally) for hypertension to persist long-term. All pressor mechanisms ultimately act by shifting the renal pressure-natriuresis relationship to the right - requiring a higher BP to achieve sodium balance.

SUMMARY TABLE: PHYSIOLOGY vs. PATHOPHYSIOLOGY

Parameter	Normal Physiology	Hypertension
BP	CO × TPR; tightly regulated	Sustained elevation; pressure-natriuresis reset
Cardiac Output	~5 L/min; adapts to metabolic need	Normal in non-obese; ↑ in obesity-HTN
TPR	Autoregulated per tissue need	↑ in most patients; often compensatory
RAAS	Activated by ↓ perfusion/volume	Chronically upregulated (even if "normal" levels are inappropriate)
SNS	Rapid BP controller	Chronically elevated in many forms; ↑ renal Na⁺ retention
NO	Vasodilatory, natriuretic	Reduced; scavenged by superoxide
Kidneys	Pressure-natriuresis is the long-term controller	Impaired; shifted curve; glomerular injury → nephron loss
Baroreceptors	Set point ~120/80	Reset upward; less responsive at normal BP
ANP	Released with volume expansion; promotes natriuresis	Elevated but may have blunted renal response

REFERENCES

Fuster and Hurst's The Heart, 15th Edition, Chapter 5: Pathophysiology of Hypertension, pp. 228-250 - primary source for this review
Histology: A Text and Atlas with Correlated Cell and Molecular Biology, Clinical Correlation: RAAS and Hypertension, pp. 1888-1890
Comprehensive Clinical Nephrology, 7th Edition, Hypertension and RAAS Blockade
Deepshikha et al., Curr Hypertens Rev, 2025 - Recent review: Hypertension Pathophysiology, Risk Factors, and Modern Management (PMID: 40051353)
Gallo & Savoia, Int J Mol Sci, 2024 - Hypertension and Heart Failure: From Pathophysiology to Treatment (PMID: 38928371)

Prepared for Post Graduate Scholar Thesis Lecture | July 2026 | Orris Medical Education

Hypertension each symptoms behind is each symptom pathophysiology for literature review

Finding Sources

Searching PubMed

"hypertension" AND "symptoms" AND "pathophysiology"

Finding Sources

Searching the Web

hypertension symptoms pathophysiology mechanism headache epistaxis palpitations edema nocturia 2024

I now have comprehensive data from the medical library (Textbook of Family Medicine, Fuster & Hurst, Braunwald's Heart Disease) plus current literature. Let me compile the complete symptom-by-symptom pathophysiology review.

LITERATURE REVIEW: HYPERTENSION - SYMPTOM-BY-SYMPTOM PATHOPHYSIOLOGY

For Post Graduate Scholar Thesis | Fuster & Hurst's The Heart, 15th Ed. | Braunwald's Heart Disease | Textbook of Family Medicine 9th Ed. | Current Literature

IMPORTANT PREFACE: THE PARADOX OF THE "SILENT KILLER"

Hypertension is classically called the "silent killer" because the majority of patients with even severe hypertension remain asymptomatic for years to decades. The pressure itself does not directly stimulate pain or discomfort - symptoms arise only when BP is high enough or sustained long enough to:

Damage blood vessel walls (endothelial dysfunction, vascular remodeling)
Injure target organs (heart, brain, kidneys, eyes, great vessels)
Exceed physiological compensatory mechanisms (autoregulation breakthrough)

A landmark 2024 population-based study from Pakistan (PMID: 39184750) confirmed that most "hypertensive symptoms" (headache, vertigo, edema, fatigue) were not statistically different between normotensive and hypertensive groups - only palpitations, vision problems, and sleep apnea showed significant association with hypertension (p < 0.05). This underscores that symptoms attributed to BP elevation are often non-specific.

SYMPTOM 1: HEADACHE

Clinical Pattern

Classically described as occipital, throbbing, worse in the morning, improving as the day progresses
Most commonly associated with severe hypertension (BP > 180/110 mmHg) and hypertensive crises
Episodic headache occurs in 80% of pheochromocytoma cases (sudden episodic BP surges)

Pathophysiology

Mechanism 1 - Cerebral Vascular Distension: In severe acute hypertension, when BP exceeds the upper limit of cerebral autoregulation (~150-180 mmHg MAP), the cerebral vasculature can no longer vasoconstrict adequately to protect the brain. Forced vasodilation of intracranial arteries occurs - stretch and distension of pain-sensitive vessel walls and meningeal structures (innervated by trigeminal C-fibers) generates pain signals. This is the "breakthrough autoregulation" mechanism.

Mechanism 2 - Increased Intracranial Pressure: In hypertensive encephalopathy and grade 4 hypertensive retinopathy, papilledema indicates raised intracranial pressure (ICP) secondary to cerebral edema. Elevated ICP stretches pain-sensitive meninges and dural venous sinuses → holocranial or occipital headache.

Mechanism 3 - Morning Predominance: Morning headaches correspond to the circadian BP surge on awakening (cortisol, catecholamine release, orthostatic activation of RAAS). Recumbent position during sleep also slightly increases ICP compared to upright posture. Both factors converge to make morning the peak risk period.

Mechanism 4 - Neurohumoral: Research from Gus et al., PMC1781314 proposes that vasopressin and endorphin (released during chronic BP elevation) have analgesic properties - paradoxically, the antinociceptive tone from chronically elevated BP may actually reduce headache perception in some patients with sustained hypertension, explaining why headache is not always proportional to BP level.

Key Point: Headache alone is an unreliable indicator of BP level. Most morning headaches in hypertensive patients may reflect obstructive sleep apnea (itself associated with hypertension) rather than elevated BP directly.

SYMPTOM 2: EPISTAXIS (NOSEBLEED)

Clinical Pattern

Posterior epistaxis (from Woodruff's plexus at the posterior nasal septum, sphenopalatine artery)
Associated with acute hypertensive crises rather than chronic stable hypertension
Prevalence in hypertensive patients: ~4% vs 1% in normotensives (2024 study)

Pathophysiology

Mechanism 1 - Increased Transmural Pressure: Chronically elevated systemic BP raises the hydrostatic pressure within the Kiesselbach's plexus (Little's area, anterior septum) and the sphenopalatine artery branches (posterior). This increased transmural pressure across fragile submucosal capillaries and arterioles - combined with any minor mechanical trauma (nose-blowing, dry air, digital trauma) - ruptures the vessel wall.

Mechanism 2 - Vascular Structural Changes: Chronic hypertension causes arteriolar remodeling - medial hypertrophy, reduced lumen-to-wall ratio, and loss of vascular compliance. These structurally abnormal vessels are paradoxically more fragile (reduced elastic reserve) and rupture more easily under pressure spikes.

Mechanism 3 - Catecholamine Surge (in Hypertensive Crisis): Sudden BP surges from catecholamine storms (pheochromocytoma, extreme stress) rapidly distend nasal submucosal vessels that lack time for autoregulatory vasoconstriction, causing acute rupture.

Mechanism 4 - Impaired Platelet Function: Severe hypertension-associated endothelial dysfunction reduces prostacyclin (PGI₂) and NO production, impairing normal hemostatic mechanisms - but this is a minor contributor compared to the mechanical pressure effect.

SYMPTOM 3: DIZZINESS AND VERTIGO

Clinical Pattern

Non-specific; among the most common complaints in hypertensive patients (62% in the 2024 Pakistan study)
BUT statistically not significantly different from normotensive population - suggesting it may reflect anxiety, medication side effects, or coexisting cerebrovascular disease

Pathophysiology

Mechanism 1 - Cerebral Hypoperfusion (Paradoxical): In patients with chronic hypertension where autoregulation is right-shifted, the lower limit of autoregulation has moved upward (e.g., from ~60 mmHg to ~100 mmHg MAP). When BP is rapidly lowered to "normal" levels (MAP 80-90 mmHg) - whether by antihypertensive drugs or spontaneous variation - cerebral blood flow may fall below the autoregulatory floor, causing orthostatic hypoperfusion → dizziness/presyncope.

Mechanism 2 - Small Vessel Disease of the Vestibular System: Chronic hypertension causes lacunar infarcts in the small perforating vessels of the brainstem and cerebellum (basilar artery territory). Microangiopathy of the labyrinthine artery (which has no collateral supply) can impair cochlear and vestibular function → vertigo, tinnitus, hearing loss.

Mechanism 3 - Posterior Fossa Ischemia: White matter hyperintensities (leukoaraiosis) from hypertensive small vessel disease in the periventricular and posterior fossa regions impair balance and spatial processing → chronic dizziness and gait instability.

Mechanism 4 - Medication-Induced: Antihypertensive drugs (particularly alpha-blockers, calcium channel blockers, and diuretics) cause postural hypotension - orthostatic dizziness within 1-3 minutes of standing due to inadequate baroreceptor-mediated compensatory vasoconstriction. This is the most common mechanism in treated hypertensives.

SYMPTOM 4: PALPITATIONS

Clinical Pattern

One of the few symptoms significantly associated with hypertension (40.1% hypertensives vs 22.7% normotensives; p < 0.001 in the 2024 study)
Characterized as awareness of rapid, forceful, or irregular heartbeat

Pathophysiology

Mechanism 1 - Left Ventricular Hypertrophy (LVH): Chronic pressure overload from hypertension → concentric LV hypertrophy (increased wall thickness, preserved or reduced cavity volume). The hypertrophied ventricle:

Has increased contractility initially → more forceful ejection → patient perceives heartbeat forcefully
Develops diastolic dysfunction (stiff ventricle, impaired relaxation) → elevated LV filling pressure → left atrial enlargement → atrial irritability
LV hypertrophy itself is arrhythmogenic (electrical remodeling, fibrosis, re-entry pathways)

Mechanism 2 - Sympathetic Nervous System Activation: Chronically elevated SNS tone in hypertension (especially obesity-related and neurogenic hypertension) directly stimulates β₁ adrenergic receptors on the SA node → sinus tachycardia, awareness of rapid heartbeat.

Mechanism 3 - Atrial Fibrillation: Hypertension is the most common risk factor for atrial fibrillation globally. The mechanism is:

LV diastolic dysfunction → ↑ LV end-diastolic pressure → ↑ left atrial pressure
Atrial wall stretch → atrial fibrosis (driven by Ang II, TGF-β, aldosterone)
Atrial remodeling → re-entry circuits → paroxysmal or persistent AF → irregular palpitations
Hypertension is responsible for 14-20% of AF attributable risk in population studies

Mechanism 4 - Catecholamine Surges (Secondary HTN): In pheochromocytoma, episodic epinephrine release causes β₁ stimulation → paroxysmal tachycardia with palpitations, pallor, diaphoresis, and severe headache (the "hypertensive paroxysm triad").

SYMPTOM 5: DYSPNEA (BREATHLESSNESS)

Clinical Pattern

Ranges from exertional dyspnea (early) to orthopnea and paroxysmal nocturnal dyspnea (advanced)
Reflects the cardiac consequences of chronic hypertension

Pathophysiology

Mechanism 1 - Diastolic Heart Failure (HFpEF): This is the most common mechanism:

Pressure overload → concentric LVH → ↓ LV compliance (stiff ventricle)
Impaired relaxation (lusitropic failure) → elevated LV filling pressures
↑ Left atrial pressure → ↑ pulmonary venous pressure → pulmonary congestion
Pulmonary interstitial/alveolar edema → activated J-receptors (juxtacapillary receptors) → stimulate vagal afferents → dyspnea sensation
Reduced lung compliance from edema → increased work of breathing → exertional dyspnea

Mechanism 2 - Systolic Heart Failure (HFrEF - Late Stage): With progressive hypertensive heart disease:

Sustained pressure overload → myocyte apoptosis, replacement fibrosis
Transition from compensated hypertrophy to dilated, failing ventricle
↓ Ejection fraction → ↓ forward output → systemic congestion + pulmonary congestion
Frank pulmonary edema in hypertensive emergency → acute severe dyspnea, pink frothy sputum

Mechanism 3 - Pulmonary Hypertension (Secondary): Chronic left-sided filling pressure elevation → pulmonary venous hypertension → reactive pulmonary arterial hypertension → right ventricular strain → dyspnea, fatigue, peripheral edema (right heart failure).

Mechanism 4 - Sleep-Disordered Breathing: Hypertension has a strong bidirectional relationship with obstructive sleep apnea (OSA):

OSA → intermittent hypoxia → SNS activation → RAAS → hypertension
OSA itself causes nocturnal dyspnea, non-restorative sleep, daytime fatigue
40% of hypertensive patients had sleep apnea vs 17.5% normotensives (2024 study, p < 0.001)

SYMPTOM 6: VISUAL DISTURBANCES

Clinical Pattern

Blurred vision, visual field defects, sudden visual loss
Statistically significantly associated with hypertension (58.7% vs 39.8%; p < 0.05)

Pathophysiology

The retinal vasculature provides a direct window into systemic vascular changes of hypertension, as it is the only part of the circulation directly visible without surgery.

Keith-Wagener-Barker / Scheie Classification of Hypertensive Retinopathy:

Grade	Vascular Change	Mechanism	Visual Symptom
Grade 1	Generalized arteriolar narrowing (silver/copper wiring); broadened light reflex	Arteriolar smooth muscle hypertrophy + intimal fibrosis → reduced lumen → increased light reflection from thickened walls	Usually asymptomatic
Grade 2	Focal arteriolar narrowing; arteriovenous (AV) nipping/nicking	Sclerosed arteriole compresses underlying vein at AV crossing (shared adventitial sheath) → venous compression, impaired venous drainage	Usually asymptomatic; risk of branch retinal vein occlusion
Grade 3	Flame hemorrhages (from arteriolar rupture), cotton-wool spots (nerve fiber layer infarcts from arteriolar occlusion), hard exudates (lipid leakage from damaged vessels)	Arteriolar necrosis → fibrinoid necrosis → rupture (hemorrhages); pre-capillary arteriolar occlusion → ischemic axoplasmic stasis in nerve fibers → cotton-wool spots	Blurred vision, scotomata
Grade 4	All Grade 3 changes + papilledema (disc swelling)	Raised ICP from hypertensive encephalopathy; or local axoplasmic stasis at optic nerve head due to disrupted axonal transport	Visual field constriction, possible sudden severe visual loss

(Source: Textbook of Family Medicine, 9th Ed., p. 3459)

Mechanism of Cotton-Wool Spots: Hypertensive arteriolar spasm/occlusion in pre-capillary arterioles → acute ischemia of retinal nerve fiber layer → blockage of axoplasmic transport → accumulation of organelles and axoplasmic material in swollen nerve fibers → white fluffy patches on fundoscopy.

Central/Branch Retinal Artery Occlusion: Hypertension is the leading risk factor. Atherosclerotic plaque in the central retinal artery or embolus from a hypertension-damaged carotid artery occludes retinal circulation → sudden painless monocular visual loss ("curtain coming down"); irreversible if not treated within 90 minutes.

SYMPTOM 7: CHEST PAIN AND ANGINA

Pathophysiology

Mechanism 1 - Supply-Demand Mismatch (Hypertensive LVH): LVH from hypertension increases myocardial oxygen demand (more muscle mass to perfuse, increased wall stress during systole). Simultaneously:

Coronary perfusion is impaired: subendocardial compression during systole is worsened by elevated LVEDP
Coronary vascular reserve is reduced: hypertensive arteriolar remodeling in intramyocardial vessels → impaired hyperemic response → microvascular angina (cardiac syndrome X)
Net: supply-demand mismatch → exertional angina without epicardial coronary stenosis

Mechanism 2 - Epicardial Coronary Artery Disease: Hypertension is a major risk factor for atherosclerosis:

Endothelial shear stress from turbulent flow → endothelial dysfunction → LDL oxidation, monocyte adhesion → foam cell formation → plaque
Ang II promotes VSMC proliferation and plaque instability
Plaque rupture → acute coronary syndrome → acute chest pain

Mechanism 3 - Aortic Dissection: Hypertension is the most common predisposing cause of aortic dissection:

Chronic pressure + pulse wave trauma → cystic medial necrosis (fragmentation of elastic lamellae, smooth muscle loss) in aortic wall
Intimal tear → blood enters media → dissecting hematoma propagates along aorta
Sudden severe "tearing" or "ripping" chest pain radiating to the back, maximal at onset - distinguishes from MI where pain builds gradually

SYMPTOM 8: EDEMA (PERIPHERAL/ANKLE SWELLING)

Pathophysiology

Mechanism 1 - Sodium and Water Retention: RAAS activation in hypertension → aldosterone → ENaC stimulation in collecting duct → Na⁺ reabsorption → water follows → expanded extracellular fluid volume → increased capillary hydrostatic pressure → transudation into interstitium → pitting edema.

Mechanism 2 - Hypertensive Heart Failure: Right-sided heart failure (from hypertension-induced left heart failure or pulmonary hypertension) → elevated central venous pressure → elevated systemic capillary hydrostatic pressure → bilateral dependent pitting edema, hepatomegaly, ascites (cardiac cirrhosis late stage).

Mechanism 3 - Calcium Channel Blocker Side Effect: A critical distinction: Dihydropyridine CCBs (amlodipine, nifedipine) cause dose-dependent, non-pitting dependent edema through preferential dilation of pre-capillary arterioles without corresponding venous dilation → increased capillary hydrostatic pressure → interstitial fluid accumulation. This is not a sign of heart failure - it does not respond to diuretics but resolves with CCB dose reduction or switching to ACE inhibitor/ARB combination (which also dilates the post-capillary venule, equalizing the pressure gradient).

Mechanism 4 - Hypertensive Nephropathy: Progressive hypertensive glomerulosclerosis → loss of albumin (proteinuria) → reduced plasma oncotic pressure → oncotic-pressure driven edema (nephrotic-type) + fluid overload from impaired renal sodium excretion.

SYMPTOM 9: NOCTURIA (EXCESSIVE NOCTURNAL URINATION)

Pathophysiology

Mechanism 1 - Loss of Nocturnal BP Dipping: Normal individuals show a 10-20% fall in BP during sleep ("dipper" pattern), mediated by reduced SNS activity and RAAS. In hypertensives - especially salt-sensitive, elderly, and those with CKD - this dipping is blunted or absent ("non-dippers" or "reverse-dippers").

During the day, peripheral edema accumulates (Na⁺ retained by upright posture + gravity). On lying down at night, fluid redistributes from the periphery back to the central circulation → increased cardiac filling → ANP release → natriuresis/diuresis → nocturia (the kidneys excrete the fluid loaded during daytime recumbency).

Mechanism 2 - Impaired Pressure-Natriuresis Curve: In hypertension, sodium excretion during the day is reduced (the pressure-natriuresis curve is right-shifted), creating a sodium/fluid debt. At night, even modest increases in renal perfusion (from supine position) may tip the kidneys into catching up on sodium excretion → compensatory nocturnal natriuresis and diuresis.

Mechanism 3 - Renal Tubular Impairment: Hypertensive nephrosclerosis → tubular dysfunction → reduced concentrating ability → polyuria and nocturia even without volume excess.

SYMPTOM 10: FATIGUE AND COGNITIVE IMPAIRMENT

Pathophysiology

Mechanism 1 - Reduced Cerebral Perfusion: Chronic hypertension → cerebral small vessel disease → white matter hyperintensities (leukoaraiosis) → slowed neural conduction, reduced processing speed → cognitive fatigue, reduced executive function, memory impairment (vascular cognitive impairment/dementia).

Mechanism 2 - Sleep Disruption: Hypertension-associated OSA → fragmented sleep → non-restorative sleep → chronic fatigue, which is then misattributed to the BP itself.

Mechanism 3 - Cardiac Output Reduction: In advanced hypertensive heart disease with diastolic or systolic dysfunction, reduced CO at peak exertion limits skeletal muscle oxygen delivery → early fatigue on exertion, reduced exercise tolerance.

Mechanism 4 - Medication Side Effects: Beta-blockers → reduced HR and CO → exertional fatigue; central-acting agents (methyldopa, clonidine) → sedation and fatigue; diuretics → hypokalemia → muscle weakness and fatigue.

SYMPTOM 11: HEMATURIA AND PROTEINURIA (RENAL SYMPTOMS)

Pathophysiology

Hypertensive Nephrosclerosis - The Cascade:

Chronic ↑ BP
    ↓
Afferent arteriolar hyalinosis (smooth muscle replaced by amorphous pink material)
    ↓
Reduced glomerular perfusion → Glomerular ischemia (benign nephrosclerosis)
              OR
Elevated glomerular capillary pressure if preglomerular resistance inadequate
    ↓
Glomerular basement membrane disruption → Proteinuria (microalbuminuria initially)
Capillary tuft rupture → Microscopic/macroscopic hematuria
    ↓
Tubular atrophy, interstitial fibrosis → Progressive CKD
    ↓
Reduced nephron mass → Further impaired pressure-natriuresis → Worsening hypertension
(vicious cycle)

Microalbuminuria (urine albumin-to-creatinine ratio > 30 mg/g) is an early marker of both hypertensive renal damage and generalized endothelial dysfunction, indicating elevated cardiovascular risk beyond the BP level alone.

SYMPTOMS SPECIFIC TO HYPERTENSIVE EMERGENCIES

When BP rises acutely and severely (typically > 180/120 mmHg with end-organ damage), a cascade of acute symptoms emerges:

Symptom	Mechanism	Clinical Syndrome
Severe headache + confusion + seizures	Breakthrough cerebral autoregulation → forced dilation → cerebral edema → raised ICP	Hypertensive Encephalopathy
Sudden focal neurological deficit	Lacunar infarct or hemorrhagic stroke from vessel rupture	Hypertensive stroke
Acute dyspnea + pink frothy sputum	Acute LV failure → pulmonary edema	Hypertensive acute pulmonary edema
Chest pain radiating to back	Aortic wall intimal tear	Acute aortic dissection
Visual loss + papilledema	Optic nerve head axoplasmic flow obstruction from ICP; retinal arteriolar necrosis	Malignant hypertension
Oliguria + hematuria	Fibrinoid necrosis of renal arterioles → acute kidney injury	Malignant hypertensive nephropathy

SUMMARY: SYMPTOM-PATHOPHYSIOLOGY MATRIX

Symptom	Primary Mechanism	Organ	BP Threshold
Headache	Cerebrovascular dilation / raised ICP / autoregulation breakthrough	Brain	Usually > 180/110
Epistaxis	Transmural pressure excess + arteriolar fragility	Nasal vessels	Acute crises
Dizziness	Cerebral hypoperfusion (right-shifted autoregulation); small vessel disease	Brain/vestibular	Variable
Palpitations	LVH + SNS activation + AF (Ang II-mediated atrial fibrosis)	Heart	Sustained HTN
Dyspnea	Diastolic dysfunction → pulmonary congestion	Heart/Lungs	Sustained HTN
Visual changes	Retinal arteriolar changes (grades 1-4); CRAO	Retina	Grades 3-4 → severe HTN
Chest pain	Microvascular angina (LVH); CAD; aortic dissection	Heart/Aorta	Sustained + severe
Edema	Na⁺ retention (RAAS) + right heart failure + hypertensive nephropathy	Kidneys/Heart	Sustained HTN
Nocturia	Non-dipping pattern + nocturnal natriuresis + tubular dysfunction	Kidneys	Sustained HTN
Fatigue	Cerebral SVD; sleep apnea; reduced CO; medications	Multi-system	Sustained HTN
Hematuria/Proteinuria	Glomerular capillary injury / arteriolar hyalinosis	Kidneys	Sustained HTN

REFERENCES

Fuster and Hurst's The Heart, 15th Edition - Blood flow regulation and hypertension pathophysiology
Textbook of Family Medicine, 9th Edition - Hypertensive retinopathy grading (Scheie's classification), pp. 3439-3459
Braunwald's Heart Disease, 12th Edition - LVH, diastolic dysfunction, hypertensive heart disease
Kidwai et al., Cureus, 2024 - High Blood Pressure-Associated Symptoms: Insights from a Population-Based Study in Pakistan (PMID: 39184750)
Gus et al., J Human Hypertension, PMC1781314 - Systemic Hypertension, Headache, and Ocular Hemodynamics: A New Hypothesis
Wang et al., J Cardiovasc Dev Dis, 2025 - Diagnosis and Management of Hypertensive Heart Disease incorporating 2023 ESH / 2024 ESC Guidelines

Prepared for Post Graduate Scholar Thesis Literature Review | July 2026 | Orris Medical Education

Make a clinical presentation flowchart for hypertensive symptoms and diagnosis

Generating Image

A comprehensive clinical presentation flowchart for hypertension symptoms and diagnosis, medical poster style suitable for postgraduate scholars. The flowchart begins at the top with a box titled "PATIENT PRESENTS WITH POSSIBLE HYPERTENSION" with an arrow pointing down. Below that, a wide box labeled "STEP 1: BLOOD PRESSURE MEASUREMENT" containing: "Seated, rested ≥5 min | Both arms | Confirmed on ≥2 separate visits | Ambulatory/Home BP monitoring if needed" Arrow down to a DIAMOND decision box: "BP ELEVATED? (≥130/80 mmHg)" Two branches - YES (right arrow) and NO (left arrow to "Reassess in 1 year / Lifestyle counseling" box) YES branch flows down to a box "STEP 2: CLASSIFY HYPERTENSION" with 4 sub-boxes side by side: - "ELEVATED: SBP 120–129 / DBP <80" - "STAGE 1: SBP 130–139 / DBP 80–89" - "STAGE 2: SBP ≥140 / DBP ≥90" - "HYPERTENSIVE CRISIS: SBP >180 / DBP >120" Below that, "STEP 3: SYMPTOM ASSESSMENT" with two columns: Left column - "COMMON SYMPTOMS" listing: Headache (occipital, morning), Dizziness/Vertigo, Palpitations, Dyspnea (exertional), Fatigue, Nocturia, Epistaxis, Visual Disturbances, Chest Pain, Peripheral Edema Right column - "EMERGENCY SYMPTOMS (Red Flags)" in red text: Severe headache + confusion, Sudden vision loss, Acute chest pain/back pain, Focal neurological deficit, Acute severe dyspnea, Oliguria/hematuria Arrow down to "STEP 4: HISTORY & PHYSICAL EXAMINATION" with 3 sub-boxes: - "Risk Factors: Age, Sex, Family Hx, Smoking, DM, Dyslipidemia, Obesity, Physical inactivity, Dietary sodium" - "Physical Exam: BMI, Waist circumference, Fundoscopy (retinopathy grading), Cardiac auscultation, Peripheral pulses, Bruits" - "Secondary HTN Clues: Renal bruit (RAS), Moon face/striae (Cushing), Paroxysmal Hx (Pheo), Young onset + hypokalemia (Conn)" Arrow down to "STEP 5: INVESTIGATIONS" with two rows: Row 1 - "MANDATORY (All Patients)": Urinalysis + ACR | Serum creatinine/eGFR | Electrolytes (Na, K) | Fasting glucose/HbA1c | Lipid profile | ECG | Chest X-ray Row 2 - "SELECTED (if secondary HTN suspected)": Renal Doppler USS | Plasma aldosterone:renin ratio | 24h urine metanephrines | Cortisol (overnight dexamethasone suppression) | CT Angiography Aorta | Echocardiogram Arrow down to "STEP 6: TARGET ORGAN DAMAGE ASSESSMENT" with 5 organ boxes in a row: - HEART: LVH on ECG/Echo, Diastolic dysfunction, Heart failure (HFpEF/HFrEF) - BRAIN: White matter lesions (MRI), Cognitive impairment, Prior stroke/TIA - KIDNEYS: Microalbuminuria, Proteinuria, Reduced eGFR, Hypertensive nephrosclerosis - EYES: Retinopathy grade 1–4 (Scheie), Papilledema, CRAO - VESSELS: Ankle-Brachial Index <0.9, Carotid IMT, Aortic dilation Arrow down to "STEP 7: DIAGNOSIS & RISK STRATIFICATION" diamond: - "PRIMARY (Essential) HTN >90%: No identifiable cause; multifactorial; exclude secondary" - "SECONDARY HTN <10%: Renovascular | Primary Hyperaldosteronism | Pheochromocytoma | Cushing | Coarctation | CKD" Final box at bottom: "STEP 8: MANAGEMENT PLAN" with 3 columns: - "LIFESTYLE: DASH diet | Sodium restriction <2.3g/day | Physical activity 150min/week | Weight loss | Smoking cessation | Alcohol moderation" - "PHARMACOTHERAPY: Stage 1 + high risk or Stage 2: ACE inhibitor/ARB + CCB ± Thiazide diuretic | Resistant HTN: Add MRA (spironolactone) | Secondary HTN: Treat underlying cause" - "FOLLOW-UP: BP target <130/80 | Monitor TOD | Annual labs | Medication adherence | Patient education" Use a clean white background, navy blue headers, red for emergency boxes, green for management, organized professional medical diagram layout with clear arrows and clean typography.

Here is the complete clinical presentation flowchart:

Hypertension Clinical Presentation & Diagnosis Flowchart

The flowchart walks through 8 sequential clinical steps:

Step	Content
Step 1	BP Measurement - correct technique, both arms, confirmation on ≥2 visits
Step 2	BP Classification - Elevated / Stage 1 / Stage 2 / Hypertensive Crisis
Step 3	Symptom Assessment - common symptoms vs. red flag emergency symptoms (severe headache+confusion, sudden vision loss, tearing chest pain, focal neurology)
Step 4	History & Physical Examination - risk factors, BMI/fundoscopy, clues to secondary HTN
Step 5	Investigations - mandatory (ECG, urine ACR, eGFR, electrolytes, lipids, glucose) vs. selected (aldosterone:renin ratio, 24h metanephrines, renal Doppler)
Step 6	Target Organ Damage Assessment - Heart / Brain / Kidneys / Eyes / Vessels
Step 7	Diagnosis - Primary HTN (>90%) vs. Secondary HTN (<10%) with specific causes
Step 8	Management - Lifestyle + Pharmacotherapy (ACEi/ARB + CCB ± thiazide) + Follow-up targets

You can right-click the image above to save or download it for your thesis presentation. If you need this as a downloadable PPTX slide or PDF poster, let me know!

This is a shared conversation. Sign in to Orris to start your own chat.